Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Bio-Techne has reached an agreement to acquire Exosome Diagnostics, putting the firm in a stronger position in the emerging liquid biopsy and precision medicine spaces.
Latest From Deals
Certain VCs are becoming reluctant to invest in medtech, citing difficulties such as a shrinking pool of buyers and increasing regulatory challenges. But Sofinnova Partners has successfully sold a medical device portfolio company – and one that is in a difficult field like renal denervation, no less – to a Japanese buyer. Antoine Papiernik, managing partner at the French VC, explains how persevering with a renal denervation technology paid-off and gives his perspective on whether medtech is still a space worth investing in.
Biodesix Inc. is acquiring Integrated Diagnostics Inc. for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. See what Biodesix CEO David Brunel said about it here.
A quartet of mega-rounds in June closed off what has been the most successful first-half since 2014, with an impressive $4.7bn of private venture funds raised in total. Digital health is one area that is evidently rising in investor popularity and potentially helping to drive these mega-rounds.
Biodesix has acquired Integrated Diagnostics for an undisclosed sum to add the XL2 lung-cancer test to its molecular diagnostics line-up and to acquire technology and expertise that can improve its biopharma business.
Medtronic's agreement to provide continuous glucose monitor and insulin pump systems to UnitedHealthcare members improved patient-outcomes in the first year, according to an analysis. See what Peter Pronovost, the insurance company's chief medical officer, said about it here.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech highlights notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we look at industry pacts that were sealed in May and June 2018.
Medtronic and UnitedHealthcare have evidence that their year-old partnership is improving health outcomes in diabetes patients that require intensive insulin delivery. An analysis of more than 6,000 UnitedHealthcare members with diabetes who used Medtronic's MiniMed 630G and previous generation insulin pumps between July 2016 and July 2017 showed 27% fewer preventable hospital admissions compared to plan-participants who were using multiple daily injections of insulin.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.